These old stories are in some cases the latest study results on the subject. What is useless is you telling us again the price has dropped from the trial result followed by the PCH. Agreed the company needs to show solid progress, and a result on the PCH is the quickest way to do that, now they have only submitted the PBT2 safety and trial design pack to the FDA. I guess they want to trial in the USA where the HSG(Huntington's Study Group) is based, and have confidence it will be lifted. Considering the urgency for a cognition drug in HD, and fairly convincing proof to date it is safe in humans, I don't know why any extra safety data could not be investigated alongside the P3.
Silence, page-19
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 122248 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 25307592 | 14 |
View Market Depth
| Last trade - 16.12pm 16/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |
Day chart unavailable